Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on trial endpoints, cash-runway tables, and licensing clauses can make Ovid Therapeutics Inc’s disclosures feel impenetrable. If you have ever typed “Ovid Therapeutics SEC filings explained simply” or wondered how a failed Phase-2 update appears in an 8-K, you know the challenge of parsing biotech jargon.
Stock Titan’s AI-powered analysis converts every Ovid Therapeutics quarterly earnings report 10-Q filing and annual report 10-K simplified into concise, decision-ready summaries. Our engine streams Ovid Therapeutics Form 4 insider transactions real-time, highlights option grants, and links each material event so you don’t have to wade through EDGAR. Need the Ovid Therapeutics proxy statement executive compensation details or to verify Ovid Therapeutics executive stock transactions Form 4? They’re surfaced instantly, alongside plain-English context.
- Track Ovid Therapeutics insider trading Form 4 transactions minutes after they post.
- Run AI-driven Ovid Therapeutics earnings report filing analysis to compare R&D spend and cash runway quarter over quarter.
- Receive alerts when an Ovid Therapeutics 8-K material events explained summary flags new clinical data or partnership news.
Whether you are understanding Ovid Therapeutics SEC documents with AI ahead of a financing round or scanning past S-3 and S-8 issuances, Stock Titan delivers complete, real-time coverage of every filing type—10-K, 10-Q, 8-K, Form 4, and more—paired with expert insight so you can make informed decisions faster.
Ovid Therapeutics Inc. reported unaudited results for the quarter ended June 30, 2025 showing $38.3 million in combined cash, cash equivalents and marketable securities and total assets of $77.4 million, down from $92.2 million at December 31, 2024. Revenue for the three months was $6.3 million versus $0.2 million a year earlier, driven primarily by a $6.3 million payment recognized in connection with the amendment to the Marinus/Immedica arrangement (with $0.7 million recorded as deferred revenue). Operating expenses declined to $11.3 million from $20.7 million, with research and development spending down to $6.5 million and general and administrative to $4.9 million.
The company recorded a net loss of $4.7 million for the quarter and $14.9 million for the six months, and has an accumulated deficit of $319.2 million and working capital of $33.2 million. Management states existing cash and securities are not sufficient to fund current operating plans through the next 12 months and is evaluating strategic alternatives. Takeda discontinued the soticlestat program and prior royalty monetization was reduced to zero; Nasdaq notified the company of a minimum bid deficiency, the company obtained approval to transfer to the Nasdaq Capital Market and authorized a potential reverse stock split option.
Ovid Therapeutics reported that it furnished a press release with business updates and its second quarter 2025 financial results as Exhibit 99.1. The Company disclosed it had not regained compliance with Nasdaq's minimum $1.00 closing bid requirement after the initial cure period and therefore will transfer its common stock to the Nasdaq Capital Market where it will continue trading under the symbol OVID.
The Nasdaq approved the transfer and granted the Company an additional 180-calendar-day compliance period through February 9, 2026 to regain the minimum bid price. The Company said it will monitor the closing bid price and may pursue options to regain compliance, including a reverse stock split, and noted that failure to regain compliance could lead to delisting with the right to appeal.
Ovid Therapeutics (NASDAQ:OVID) has amended its Exclusive Patent License Agreement with Immedica Pharma AB through Amendment No. 1, effective June 23, 2025. The key modification involves Immedica purchasing ongoing royalty obligations for $7.0 million in cash, payable within 10 business days. The original agreement granted Marinus (now an Immedica subsidiary) exclusive rights to ganaxolone for CDKL5 deficiency disorder treatment in the US and Europe. The amendment also provides Immedica with additional patent prosecution rights and anticipates a second amendment within six months to expand territory coverage and rights to other necessary patents.
Form 4 overview: Director Kevin J. Fitzgerald of Ovid Therapeutics Inc. (NASDAQ: OVID) reported the grant of a stock option for 45,000 shares on 02/20/2025 at an exercise price of $0.57 per share.
The option is classified as an acquisition (Code “A”) of derivative securities. It will vest 100 % on 02/20/2026, provided the director remains in continuous service, and will expire on 02/19/2035. Following the transaction, Fitzgerald beneficially owns 45,000 derivative securities, all held directly.
No common-stock transactions, sales, or additional derivative dispositions were reported. Because this filing reflects a routine director equity grant rather than an open-market purchase or sale, it typically has limited immediate trading impact but does strengthen long-term alignment between the director and shareholders.
Form 4 Filing Details: Bart Friedman, Director of Ovid Therapeutics (OVID), received a stock option grant for 45,000 shares of common stock on February 20, 2025. The filing was reported on June 28, 2025.
Key Transaction Terms:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
- Transaction reported as a Direct (D) ownership
This grant appears to be part of the company's director compensation program. The significant discount in the exercise price compared to typical market prices could indicate either a period of stock price decline or a deliberate incentive structure to align director interests with shareholders.
Insider Trading Alert: Barbara Gayle Duncan, Director at Ovid Therapeutics (OVID), received a stock option grant on February 20, 2025. The transaction details include:
- Granted 45,000 stock options to purchase common stock
- Exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
This Form 4 filing, reported by the director's attorney-in-fact Jason Minio on June 18, 2025, represents a standard equity compensation grant for board service. The relatively low exercise price and one-year cliff vesting schedule suggest this is part of the company's regular director compensation program.
Ovid Therapeutics director Karen Bernstein received a stock option grant for 45,000 shares of common stock on February 20, 2025. The key details of this Form 4 filing include:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Expiration date is set for February 19, 2035
- The derivative securities are held directly by the reporting person
This grant represents a standard director compensation package and aligns the director's interests with shareholders through long-term equity incentives. The one-year cliff vesting schedule encourages retention while the ten-year exercise window provides flexibility in execution timing.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
